Search

Search Constraints

You searched for: Author/Creator Orlando, Rosalba

Search Results

1. A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. Issue 1 (8th June 2020)

2. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Issue 12 (December 2020)

3. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. (6th October 2018)

4. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Issue 12 (December 2018)

5. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Issue 9 (17th January 2017)

6. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. Issue 9 (November 2020)

7. Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study. Issue 9 (1st November 2020)

9. Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. Issue 2 (27th December 2018)

10. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Issue 2 (February 2017)